Injectable Collagen Line · National Growth Campaign
Visits -14%, average ticket +19.7%: rebuilding product strength
2026.01 – 2026.09 (equal-window comparison) · Client: Group product office of a premium chain (anonymized)
| Item | Fact | Definition / note |
|---|---|---|
| Client-delivered revenue | RMB 21.205M | +2.9% YoY, equal window |
| Visit count | 861 | −14.0%; from 1,001 |
| Average ticket | RMB 24,628 | +19.7%; from 20,577 |
| YTD collagen revenue | RMB 21.704M | As of 2026.10.01, CRM dashboard, +5.4% YoY |
Full case file
Background
Injectable collagen is a default category for every premium practice; the high end uses dual-beauty Type I and top domestic Type III collagens. Yet the industry cannot answer three questions: why it works, why so many sessions are needed, and why it is used in China when it is not abroad. In 2026 category competition went white-hot; store count and category revenue were both falling. I rebuilt this product line as group product lead.
Symptoms
Four problems stacked: white-hot category competition; store count and category both declining with unclear attribution; pricing, course and cost definitions inconsistent across sites so data would not aggregate; and product usage plus aftercare gaps dragging both outcomes and repurchase.
If one of these is yours, that is our work
- White-hot category competition
- Store/category decline with unclear attribution
- Inconsistent definitions across sites
- Cannot explain why multiple sessions
Diagnosis
Three moves.
Definitions first. Rebuild line data on the consumption definition, strip store-count interference, make growth attributable before pursuing it.
Education is the root. Every practice carries collagen; nobody can explain why it works: the industry sells devices, not mechanisms.
Enter through ECM. Aging's core is the MMPs mechanism: metalloproteinases continuously degrading collagen chains. Type I supports structure while Type III resets inflamed skin; ECM optimization must be continuous, not one micro-crosslinked hyaluronic shot.
Actions
Teach the MMPs mechanism until the client's three questions get straight answers.
Unify pricing, course and cost definitions across all national sites; design intervention cadence by client life cycle.
Anchor value with a horizontal benchmark: 'Collagen benchmarks: domestic top Type III 4mg vs. imported collagen 12mg': and refuse the price war.
Rebuild product usage and aftercare together, landing product strength in course design. And set the rule: any new product line entering a store must carry its pricing ladder, course structure and script package.
Results
- Equal-window YoY (2025.01–09 vs. 2026.01–09):
- Client-delivered revenue RMB 20.598M → 21.205M (+2.9%)
- Visits 1,001 → 861 (−14.0%); buyers 490 → 461 (−5.9%). Courses shift to fewer, more effective sessions with higher units per session
- Average ticket RMB 20,577 → 24,628 (+19.7%)
- YTD injectable-collagen revenue RMB 21.704M as of 2026.10.01 (CRM dashboard, +5.4% YoY)
Verification
The value of these numbers is in the definitions: delivered revenue is true net income, gifts excluded; visits are deduplicated by unique ID; all YoY uses equal windows: ratios without equal windows do not enter the report. Visits down 14% with ticket up 19.7% coexist in a comparable window: the structure proves 'fewer but deeper' product strength, not a traffic play.
Principal’s read · SAM Chengjun Xu
Visits fell and we still grew: if aggressive ticket-building proves anything, it is that the ECM concept works.